Translating scientific breakthroughs into first-in-class treatments
Novel insights into human biology define our development programs that target cancer
Pipeline Overview
Our oncology pipeline is focused on restoring and bolstering immune responses. Tizona is completing its Phase 1b clinical trial (NCT04485013) evaluating TTX-080 both as monotherapy and in combination with pembrolizumab and cetuximab in patients with advanced cancers. Based on initial clinical findings from the trial, the company is currently planning for Phase 2 development.
HLA-G, a Novel Immune Checkpoint
HLA-G is normally expressed at the maternal-fetal interface and certain sites of immune privilege. In cancer, its expression is used as an immune evasion strategy. HLA-G mediates its potent suppression through binding to receptors found on tumor infiltrating immune cells.
TTX-080, a first-in-class Anti-HLA-G Antibody
